The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Jing Zou; Xuping Xie; Camila R. Fontes-Garfias; Kena A. Swanson; Isis Kanevsky; Kristin Tompkins; Mark Cutler; David Cooper; Philip R. Dormitzer; Pei Yong Shi

doi:10.1038/s41541-021-00313-8

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Jing Zou
, Xuping Xie
, Camila R. Fontes-Garfias
, Kena A. Swanson
, Isis Kanevsky
, Kristin Tompkins
, Mark Cutler
, David Cooper
, Philip R. Dormitzer
, Pei Yong Shi

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

Original language	English (US)
Article number	44
Journal	npj Vaccines
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/s41541-021-00313-8
State	Published - Dec 2021

ASJC Scopus subject areas

Immunology
Pharmacology
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1038/s41541-021-00313-8

Cite this

@article{1f3b09949678400a8eac0da690c8a869,

title = "The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization",

abstract = "Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95\% vaccine efficacy observed in clinical trial.",

author = "Jing Zou and Xuping Xie and Fontes-Garfias, \{Camila R.\} and Swanson, \{Kena A.\} and Isis Kanevsky and Kristin Tompkins and Mark Cutler and David Cooper and Dormitzer, \{Philip R.\} and Shi, \{Pei Yong\}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41541-021-00313-8",

language = "English (US)",

volume = "6",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

AU - Zou, Jing

AU - Xie, Xuping

AU - Fontes-Garfias, Camila R.

AU - Swanson, Kena A.

AU - Kanevsky, Isis

AU - Tompkins, Kristin

AU - Cutler, Mark

AU - Cooper, David

AU - Dormitzer, Philip R.

AU - Shi, Pei Yong

PY - 2021/12

Y1 - 2021/12

N2 - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

AB - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

UR - https://www.scopus.com/pages/publications/85103430539

UR - https://www.scopus.com/pages/publications/85103430539#tab=citedBy

U2 - 10.1038/s41541-021-00313-8

DO - 10.1038/s41541-021-00313-8

M3 - Article

C2 - 33767200

AN - SCOPUS:85103430539

SN - 2059-0105

VL - 6

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 44

ER -

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this